Alpha 2.0
Login Register
» Authors » Ivanka Krznaric

Ivanka Krznaric

Explore the profile of Ivanka Krznaric including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 25
Citations 896
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Microbiology
Top 10 Co-Authors
Christoph D Spinner
Christoph Boesecke
Patrick Ingiliz
Tim Kummerle
Eva Wolf
Christiane Cordes
Knud Schewe
Axel Baumgarten
Jurgen K Rockstroh
Markus Bickel
Published In
Infection
J Int AIDS Soc
HIV Med
AIDS
PLoS One
Affiliations
Soon will be listed here.
Recent Articles
1.
Recently acquired HCV infection in men who have sex with men in Germany in the direct-acting antivirals era and during the COVID-19 pandemic
Ingiliz P, Lutz T, Schewe K, Baumgarten A, Krznaric I, Mauss S, et al.
HIV Med . 2024 May; 25(8):967-975. PMID: 38812289
Introduction: Direct-acting antivirals (DAAs) are key to eliminating hepatitis C virus (HCV). In men who have sex with men (MSM) with HIV co-infection, recently acquired HCV infection is common. Sexual...
2.
Still trouble with bleeding: Risk factors for HCV transmission in men who have sex with men and behavioural trajectories from 2019 to 2021
Schmidt A, Weatherburn P, Wang H, Lutz T, Schewe K, Mauss S, et al.
HIV Med . 2024 May; 25(8):976-989. PMID: 38803112
Objectives: To identify sexual/sex-associated risk factors for hepatitis C transmission among men who have sex with men (MSM) and visualise behavioural trajectories from 2019 to 2021. Methods: We linked a...
3.
Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER Trial
Cespedes M, Das M, Yager J, Prins M, Krznaric I, De Jong J, et al.
Transgend Health . 2024 Feb; 9(1):46-52. PMID: 38312459
Purpose: Transgender women are disproportionately affected by HIV and are underutilizing preexposure prophylaxis (PrEP). The lower uptake of PrEP by transgender women may be, in part, owing to the perception...
4.
Establishing a framework towards monitoring HCV microelimination among men who have sex with men living with HIV in Germany: A modeling analysis
Marquez L, Ingiliz P, Boesecke C, Krznaric I, Schewe K, Lutz T, et al.
PLoS One . 2022 May; 17(5):e0267853. PMID: 35551326
Background: Prior to direct-acting antivirals (DAAs), HCV incidence rose among men who have sex with men (MSM) living with HIV infection in Germany despite high hepatitis C virus (HCV) treatment...
5.
Switching to a NRTI-free 2 drug regimen (2DR) -a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changes
Monin M, Kummerle T, Schneider J, Cordes C, Heiken H, Stellbrink H, et al.
HIV Res Clin Pract . 2022 Mar; 23(1):15-21. PMID: 35234092
Switching from a three-drug regimen (3DR: boosted darunavir [bDRV] and two nucleoside reverse transcriptase inhibitors [NRTIs]) to a two-drug regimen (2DR: bDRV and dolutegravir [DTG]) demonstrated non-inferiority with regard to...
6.
Outcomes of men with HIV and germ cell cancer: Results from an international collaborative study
Hentrich M, Bower M, Daugaard G, Dieing A, Bickel M, Berretta M, et al.
Cancer . 2021 Sep; 128(2):260-268. PMID: 34592009
Background: Previous studies have shown that men with HIV and germ cell cancer (HIV-GCC) have inferior overall survival (OS) in comparison with their HIV-negative counterparts. However, little information is available...
7.
Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
Wolf E, Boesecke C, Balogh A, Bidner H, Cordes C, Heiken H, et al.
AIDS Res Ther . 2021 Sep; 18(1):58. PMID: 34496848
Objective: The DUALIS study showed that switching to boosted darunavir (bDRV) plus dolutegravir (DTG; 2DR) was non-inferior to continuous bDRV plus 2 nucleoside/nucleotide reverse-transcriptase inhibitors (NRTIs; 3DR) in treatment-experienced virologically...
8.
Health-related quality-of-life in people living with HIV after switching to dual therapy with ritonavir-boosted darunavir + dolutegravir: a DUALIS sub-study
Olliges E, Buhrlen B, Fischer F, Boesecke C, Kummerle T, Schneider J, et al.
AIDS Care . 2021 Apr; 34(6):698-707. PMID: 33896276
The DUALIS study demonstrated efficacy and safety of switching to dolutegravir plus ritonavir-boosted darunavir (DRV/r) (2DR) as compared to standard-of-care-therapy with two nucleoside reverse transcriptase inhibitors + DRV/r (3DR) in...
9.
Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study
Spinner C, Kummerle T, Schneider J, Cordes C, Heiken H, Stellbrink H, et al.
Open Forum Infect Dis . 2020 Sep; 7(9):ofaa356. PMID: 32965277
Background: Dolutegravir (DTG) and boosted darunavir (bDRV) are potent antiretrovirals with a high resistance barrier and might be valuable switch options for people with HIV (PWH). Methods: DUALIS, a randomized,...
10.
COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients
Harter G, Spinner C, Roider J, Bickel M, Krznaric I, Grunwald S, et al.
Infection . 2020 May; 48(5):681-686. PMID: 32394344
Introduction: Data on people living with human immunodeficiency virus (PLWH) in the current SARS-CoV-2 pandemic are still scarce. This case series of 33 PLWH patients with COVID-19 reveals symptoms and...